Prognostic prediction models for clinical outcomes in patients diagnosed with visceral leishmaniasis: protocol for a systematic review

被引:2
作者
Wilson, James [1 ,2 ]
Chowdhury, Forhad [1 ,2 ]
Hassan, Shermarke [1 ,2 ]
Harriss, Elinor K. [3 ]
Alves, Fabiana [4 ]
Dahal, Prabin [1 ,2 ]
Stepniewska, Kasia [1 ,2 ]
Guerin, Philippe J. [1 ,2 ]
机构
[1] Univ Oxford, Infect Dis Data Observ IDDO, Oxford, England
[2] Univ Oxford, Ctr Trop Med & Global Hlth, Oxford, England
[3] Univ Oxford, Bodleian Hlth Care Lib, Oxford, England
[4] Drugs Neglected Dis Initiat, Geneva, Switzerland
来源
BMJ OPEN | 2023年 / 13卷 / 10期
基金
比尔及梅琳达.盖茨基金会;
关键词
Prognosis; Neglected Diseases; INFECTIOUS DISEASES; Systematic Review; STATISTICS & RESEARCH METHODS; Protocols & guidelines; BIAS; RISK; TOOL;
D O I
10.1136/bmjopen-2023-075597
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction Visceral leishmaniasis (VL) is a neglected tropical disease responsible for many thousands of preventable deaths each year. Symptomatic patients often struggle to access effective treatment, without which death is the norm. Risk prediction tools support clinical teams and policymakers in identifying high-risk patients who could benefit from more intensive management pathways. Investigators interested in using their clinical data for prognostic research should first identify currently available models that are candidates for validation and possible updating. Addressing these needs, we aim to identify, summarise and appraise the available models predicting clinical outcomes in VL patients. Methods and analysis We will include studies that have developed, validated or updated prognostic models predicting future clinical outcomes in patients diagnosed with VL. Systematic reviews and meta-analyses that include eligible studies are also considered for review. Conference abstracts and educational theses are excluded. Data extraction, appraisal and reporting will follow current methodological guidelines. Ovid Embase; Ovid MEDLINE; the Web of Science Core Collection, SciELO and LILACS are searched from database inception to 1 March 2023 using terms developed for the identification of prediction models, and with no language restriction. Screening, data extraction and risk of bias assessment will be performed in duplicate with discordance resolved by a third independent reviewer. Risk of bias will be assessed using the Prediction model Risk Of Bias ASsessment Tool (PROBAST). Tables and figures will compare and contrast key model information, including source data, participants, model development and performance measures, and risk of bias. We will consider the strengths, limitations and clinical applicability of the identified models. Ethics and dissemination Ethics approval is not required for this review. The systematic review and all accompanying data will be submitted to an open-access journal. Findings will also be disseminated through the research group's website (www.iddo.org/research-themes/visceral-leishmaniasis) and social media channels.
引用
收藏
页数:6
相关论文
共 34 条
  • [1] Prognosis and prognostic research: validating a prognostic model
    Altman, Douglas G.
    Vergouwe, Yvonne
    Royston, Patrick
    Moons, Karel G. M.
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2009, 338 : 1432 - 1435
  • [2] The relationship between leishmaniasis and AIDS:: the second 10 years
    Alvar, Jorge
    Aparicio, Pilar
    Aseffa, Abraham
    Den Boer, Margriet
    Canavate, Carmen
    Dedet, Jean-Pierre
    Gradoni, Luigi
    Ter Horst, Rachel
    Lopez-Velez, Rogelio
    Moreno, Javier
    [J]. CLINICAL MICROBIOLOGY REVIEWS, 2008, 21 (02) : 334 - +
  • [3] Recent Development of Visceral Leishmaniasis Treatments: Successes, Pitfalls, and Perspectives
    Alves, Fabiana
    Bilbe, Graeme
    Blesson, Severine
    Goyal, Vishal
    Monnerat, Severine
    Mowbray, Charles
    Ouattara, Gina Muthoni
    Pecoul, Bernard
    Rijal, Suman
    Rode, Joelle
    Solomos, Alexandra
    Strub-Wourgaft, Nathalie
    Wasunna, Monique
    Wells, Susan
    Zijlstra, Eduard E.
    Arana, Byron
    Alvar, Jorge
    [J]. CLINICAL MICROBIOLOGY REVIEWS, 2018, 31 (04)
  • [4] [Anonymous], Veritas Health Innovation
  • [5] Risk Factors for Adverse Prognosis and Death in American Visceral Leishmaniasis: A Meta-analysis
    Belo, Vinicius Silva
    Struchiner, Claudio Jose
    Barbosa, David Soeiro
    Leandro Nascimento, Bruno Warlley
    Pereira Horta, Marco Aurelio
    da Silva, Eduardo Sergio
    Werneck, Guilherme Loureiro
    [J]. PLOS NEGLECTED TROPICAL DISEASES, 2014, 8 (07):
  • [6] Leishmaniasis
    Burza, Sakib
    Croft, Simon L.
    Boelaert, Marleen
    [J]. LANCET, 2018, 392 (10151) : 951 - 970
  • [7] Systematic review of clinical trials assessing the therapeutic efficacy of visceral leishmaniasis treatments: A first step to assess the feasibility of establishing an individual patient data sharing platform
    Bush, Jacob T.
    Wasunna, Monique
    Alves, Fabiana
    Alvar, Jorge
    Olliaro, Piero L.
    Otieno, Michael
    Sibley, Carol Hopkins
    Wourgaft, Nathalie Strub
    Guerin, Philippe J.
    [J]. PLOS NEGLECTED TROPICAL DISEASES, 2017, 11 (09):
  • [8] Conflict and kala-azar: Determinants of adverse outcomes of kala-azar among patients in Southern Sudan
    Collin, S
    Davidson, R
    Ritmeijer, K
    Keus, K
    Melaku, Y
    Kipngetich, S
    Davies, C
    [J]. CLINICAL INFECTIOUS DISEASES, 2004, 38 (05) : 612 - 619
  • [9] Collins GS, 2015, ANN INTERN MED, V162, P55, DOI [10.1136/bmj.g7594, 10.1016/j.jclinepi.2014.11.010, 10.7326/M14-0697, 10.1038/bjc.2014.639, 10.7326/M14-0698, 10.1016/j.eururo.2014.11.025, 10.1186/s12916-014-0241-z, 10.1002/bjs.9736]
  • [10] How to conduct a systematic review and meta-analysis of prognostic model studies
    Damen, Johanna A. A.
    Moons, Karel G. M.
    van Smeden, Maarten
    Hooft, Lotty
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2023, 29 (04) : 434 - 440